Charles River Laboratories International, Inc. (CRL)
134.98 USD -8.55 (-5.96%) Volume: 0.83M
Charles River Laboratories International, Inc.’s stock price currently stands at 134.98 USD, experiencing a decline of -5.96% this trading session with a trading volume of 0.83M, reflecting a significant YTD percentage change of -26.88%, indicating a challenging market performance for CRL.
Latest developments on Charles River Laboratories International, Inc.
Charles River Laboratories International Inc. (CRL) saw its stock underperform on Wednesday compared to its competitors, trading down 3.98% on May 21. This decline came amidst news of a leadership change at Ginkgo Bioworks, a company closely linked to Charles River Laboratories. Investors are now questioning whether to continue holding Charles River stock in their portfolios, especially after the release of drug development inputs and services stocks’ Q1 results, which included benchmarking Charles River Laboratories (NYSE:CRL).
A look at Charles River Laboratories International, Inc. Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 3 | |
| OVERALL SMART SCORE | 2.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Charles River Laboratories International, Inc. provides research tools and support services for drug discovery and development. The company offers animal research models needed for creating new drugs, devices, and therapies. With a mixed outlook according to Smartkarma Smart Scores, Charles River Laboratories scores well in value, growth, resilience, and momentum, but lags in the dividend category. This suggests a positive long-term outlook for the company overall.
Despite a lower score in the dividend category, Charles River Laboratories shows strength in value, growth, resilience, and momentum according to Smartkarma Smart Scores. This indicates that the company is well-positioned for long-term success in providing research tools and support services for pharmaceutical and biotechnology companies, hospitals, and academic institutions. Overall, the outlook for Charles River Laboratories appears promising based on its Smart Scores across various factors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
